Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
1-Minute Consult

How do we maximize diuresis in acute decompensated heart failure?

Saeid Mirzai, DO, Christopher N. Kanaan, MD, Felix Berglund, MD, Maria Mountis, DO and Heba Wassif, MD, MPH
Cleveland Clinic Journal of Medicine October 2022, 89 (10) 561-565; DOI: https://doi.org/10.3949/ccjm.89a.22016
Saeid Mirzai
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher N. Kanaan
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Berglund
Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Mountis
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Find this author on Cleveland Clinic
Heba Wassif
Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH; Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

In patients with acute decompensated heart failure (ADHF), the initial diuretic regimen should maximize intravenous loop diuretics based on urine output or spot urine sodium. Combination therapy can be used if diuretic resistance occurs.

ADHF accounts for more than 1 million hospitalizations per year in the United States, and inadequate diuresis is a common cause of readmissions and higher mortality.1 In the absence of cardiogenic shock, ADHF manifestations are driven primarily by expansion of extracellular fluid volume, leading to elevated cardiac filling pressures and congestion (edema, dyspnea, and orthopnea).2,3 Despite the evidence supporting guideline-directed medical therapy, studies guiding diuresis are limited.

LOOP DIURETICS

Loop diuretics are the cornerstone of ADHF management. Their early administration is linked to lower in-hospital mortality rates.2 Furosemide, torsemide, and bumetanide are the most used (Table 1).1,4,5 Torsemide and bumetanide have better bioavailability than furosemide, and data suggest torsemide superiority, given its possible improved outcomes and mitigation of cardiac fibrosis.3

View this table:
  • View inline
  • View popup
TABLE 1

Commonly used diuretics and doses in chronic heart failure

Initial dosing

Loop diuretics have a steep dose-response curve with little natriuretic effect until an individualized threshold is reached, and maximum natriuretic effect once the ceiling dose is achieved (Figure 1).2 Dose increases beyond the ceiling may increase the duration of natriuresis rather than the rate by maintaining the diuretic concentration above the threshold for longer. The dose-response relationship is log-linear, meaning the dose should be adjusted in a logarithmic fashion (eg, an increase from 20 mg to 40 mg is greater than 220 mg to 240 mg).3

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Loop diuretic dose-response curves in patients with heart failure (green line) and without heart failure (blue line). Heart failure shifts the curve down and to the right, translating to the need for higher doses of diuretics to achieve the same degree of diuresis and decreased maximal diuretic response.

FENa = fractional excretion of sodium

Based on data from reference 2.

Regarding initial dosing, the DOSE trial (Diuretic Optimization Strategies Evaluation)4,6 found better symptom improvement with aggressive intravenous loop diuretic dosing 2.5 times the total daily oral dose compared to a numerically equal dose. There is conflicting evidence about the relationship between diuretic dosing, renal dysfunction, and clinical outcomes.3,7 In general, to avoid premature cessation of diuretic therapy, doubling of creatinine or an increase greater than 1 mg/dL (instead of > 0.3 mg/dL) has been suggested as true renal dysfunction requiring further workup.2

Recent data suggest that using urine output and spot urine sodium to predict short-term responsiveness to intravenous loop diuretics in ADHF permits more timely adjustments to therapy (Figure 2).1–3 With this approach, if the goal of a urine output of more than 150 mL/hour or a urine sodium greater than 50 to 70 mEq/L is not achieved at 2 hours after the initial dose, the dose should be doubled and the parameters rechecked 2 hours after the repeat dose until the goals are met. When the goals are met, the same dose can be administered every 6 to 12 hours until volume overload resolves.3 Continuous furosemide infusion is also commonly used in refractory cases, given favorable pharmacodynamics with concentration maintenance above the threshold. The DOSE trial showed no difference in efficacy between continuous and intermittent dosing, but loading doses were not given at infusion initiation.5

FIGURE 2
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2

Algorithm for initiation (day 1) of diuretic titration in patients with acute decompensated heart failure.

aHigher dose for reduced glomerular filtration rate.

bSee Table 1 for maximum recommended total daily dosing. IV = intravenous; UNa = urine sodium; UOP = urine output

Based on data from references 1 and 2.

DIURETIC RESISTANCE

Diuretic resistance is defined as persistent congestion with inadequate response to escalating diuretic doses.1 Although there is no consensus on a precise metric, the inability to meet short-term urine sodium goals (Figure 2) can predict diuretic resistance. The proposed quantitative definition is failure to increase urine sodium by 90 mEq/L despite high-dose oral furosemide (160 mg twice daily or equivalent) over 3 days.7

Loop diuretics achieve their effect primarily by secretion into tubular fluid by proximal organic anion transporters, a process dependent on renal blood flow and serum pH.7 The response to loop diuretics may be diminished due to genetic polymorphisms altering transport and metabolism,8 low absorption from gut edema (as may occur with oral furosemide), low plasma protein content (> 90% protein-bound), and low renal function or perfusion (particularly with nonsteroidal anti-inflammatory drugs or possibly aspirin).3 Dietary sodium restriction nonadherence must also be ruled out since postdiuretic sodium retention can mimic true diuretic resistance.3 Renin-angiotensin system activation may also contribute, but distal tubular cell hypertrophy with increased sodium resorption is emerging as the primary mechanism of diuretic resistance.3

OPTIONS FOR AUGMENTING DIURESIS

Several options exist to augment diuresis. However, most experts recommend delaying combination therapy until loop diuretic dosing is optimized (Figure 2), to avoid risks of renal dysfunction and electrolyte abnormalities.3

First-line therapy: thiazide diuretics

Thiazide diuretics overcome the increased sodium avidity of the distal convoluted tubule that occurs with chronic loop diuretic use.5,9 Commonly used thiazide diuretics are metolazone and hydrochlorothiazide, but other options have similar efficacy and adverse-event rates (Table 1).9 The current guidelines for thiazide use are based on small studies3,9 and the CARRESS-HF trial (Cardiorenal Rescue Study in Acute Decompensated Heart Failure),10 where thiazides used in a stepwise pharmacologic algorithm were compared with ultrafiltration.

Second-line therapy: acetazolamide, potassium-sparing diuretics

Although a poor diuretic on its own, the carbonic anhydrase inhibitor acetazolamide has been shown to augment the loop diuretic effect through decreased sodium bicarbonate reabsorption in the proximal tubules (Table 1). This allows more sodium delivery to the loop of Henle, but tolerance develops after 72 hours.1 Acetazolamide also has intrinsic renal vasodilatory effects and blocks the pendrin system of chloride-bicarbonate exchange in the distal nephron.1,11 Combination therapy with acetazolamide has shown greater decongestion success compared with loop diuretics alone in the recent ADVOR trial (Acetazolamide in Decompensated Heart Failure With Volume Overload),12 without significant differences in adverse events or the secondary end points of death or rehospitalization.

The potassium-sparing diuretics amiloride and triamterene inhibit distal epithelial sodium channels in the collecting duct. Anecdotal evidence suggests amiloride can result in decongestion, but randomized clinical trials are lacking, and these medications can lead to severe hyperkalemia.2 Spironolactone works on a separate receptor to cause mild natriuresis, and it reduces potassium wasting of loop and thiazide diuretics. Data are limited regarding its synergistic use with loop diuretics in ADHF. The ATHENA-HF trial (Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure)13,14 found no difference in outcomes with this regimen; however, the patient sample did not exhibit diuretic resistance, and the 4 days of therapy may have been inadequate for response (spironolactone is a prodrug).

Alternatives

Tolvaptan. Vasopressin levels are increased in heart failure, worsening fluid retention. The selective V2 vasopressin receptor antagonist tolvaptan blocks distal tubule reabsorption of free water. It has been shown to improve filling pressures when combined with loop diuretics. It may be preferable in patients with hyponatremia and kidney dysfunction, but no improved outcomes have been seen.13 A moderate-sized cohort study comparing metolazone, chlorothiazide, and tolvaptan has shown excellent weight loss with no significant difference between the groups.15 Conivaptan has also demonstrated promising diuresis augmentation in heart failure without adverse renal or hemodynamic effects.16

Sodium-glucose cotransporter 2 inhibitors decrease proximal sodium absorption. Strong evidence from clinical trials shows significant diuresis with renoprotection and improved heart failure outcomes, but coadministration with loop diuretics has not been studied.1

Hypertonic saline. Intravenous hypertonic saline has been shown to augment diuresis by improving renal perfusion by osmotic “pulling” of free water into the intravascular space and by improving the loop diuretic effect through better sodium delivery to the loop of Henle.13 It also improves inotropy through myocardial stimulation.1 This method has been associated with reduced mortality rates, hospital length of stay, and treatment cost compared with furosemide alone.1

Ultrafiltration. Methods such as ultrafiltration can be used in congestion that is refractory to medical therapy. Outpatient peritoneal dialysis has been described for advanced heart failure with cardiorenal syndrome.13 However, there is no evidence favoring ultrafiltration over loop diuretics as first-line therapy.2

Hemodynamic evaluation. An invasive hemodynamic evaluation should be considered in hospitalized patients who have refractory symptoms despite adequate diuresis, worsening renal failure with increasing diuretics, or repeated hospitalization.17 Wireless implantable pulmonary artery pressure monitors showed promising results in the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III HF Patients) trial,18 in which patients with persistent symptoms who were randomized to receive a monitor had a 28% relative reduction in heart failure hospitalization rates.

THE BOTTOM LINE

ADHF is a major source of healthcare spending in the United States, with many hospital discharges complicated by readmissions due to inadequate diuresis. The initial goal should always be to maximize loop diuretic therapy using urine output or urinary sodium for guidance. Combination therapy can be used when patients respond poorly to escalating loop diuretic doses.

DISCLOSURES

The authors report no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2022 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Acar S,
    2. Sanli S,
    3. Oztosun C, et al
    . Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. Int Urol Nephrol 2021; 53(9):1839–1849. doi:10.1007/s11255-020-02704-7
    OpenUrlCrossRef
  2. ↵
    1. Mullens W,
    2. Damman K,
    3. Harjola VP, et al
    . The use of diuretics in heart failure with congestion—a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(2):137–155. doi:10.1002/ejhf.1369
    OpenUrlCrossRefPubMed
  3. ↵
    1. Felker GM,
    2. Ellison DH,
    3. Mullens W,
    4. Cox ZL,
    5. Testani JM
    . Diuretic therapy for patients with heart failure: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75(10):1178–1195. doi:10.1016/j.jacc.2019.12.059
    OpenUrlCrossRef
  4. ↵
    1. Felker GM,
    2. O’Connor CM,
    3. Braunwald E
    . Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009; 2:56–62. doi:10.1161/CIRCHEARTFAILURE.108.821785
    OpenUrlFREE Full Text
  5. ↵
    1. Yancy CW,
    2. Jessup M,
    3. Bozkurt B, et al
    . 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16):e14–e239. doi:10.1016/j.jacc.2013.05.019
    OpenUrlCrossRef
  6. ↵
    1. Felker GM,
    2. Lee KL,
    3. Bull DA, et al
    . Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797–805. doi:10.1056/NEJMoa1005419
    OpenUrlCrossRefPubMed
  7. ↵
    1. Wilcox CS,
    2. Testani JM,
    3. Pitt B
    . Pathophysiology of diuretic resistance and its implications for the management of chronic heart failure. Hypertension 2020; 76(4):1045–1054. doi:10.1161/HYPERTENSIONAHA.120.15205
    OpenUrlCrossRef
  8. ↵
    1. Matthaei J,
    2. Brockmöller J,
    3. Tzvetkov MV, et al
    . Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther 2015; 98(6):611–621. doi:10.1002/cpt.258
    OpenUrlCrossRefPubMed
  9. ↵
    1. Jentzer JC,
    2. DeWald TA,
    3. Hernandez AF
    . Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56(19):1527–1534. doi:10.1016/j.jacc.2010.06.034
    OpenUrlFREE Full Text
  10. ↵
    1. Bart BA,
    2. Goldsmith SR,
    3. Lee KL, et al
    . Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367(24):2296–2304. doi:10.1056/NEJMoa1210357
    OpenUrlCrossRefPubMed
  11. ↵
    1. Cil O,
    2. Haggie PM,
    3. Phuan PW,
    4. Tan JA,
    5. Verkman AS
    . Small-molecule inhibitors of pendrin potentiate the diuretic action of furosemide. J Am Soc Nephrol 2016; 27(12):3706–3714. doi:10.1681/ASN.2015121312
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Mullens W,
    2. Dauw J,
    3. Martens P, et al
    . Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 2022;10.1056/NEJMoa2203094. doi:10.1056/NEJMoa2203094
    OpenUrlCrossRef
  13. ↵
    1. Rahman R,
    2. Paz P,
    3. Elmassry M, et al
    . Diuretic resistance in heart failure. Cardiol Rev 2021; 29(2):73–81. doi:10.1097/CRD.0000000000000310
    OpenUrlCrossRef
  14. ↵
    1. Butler J,
    2. Anstrom KJ,
    3. Felker GM, et al
    . Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol 2017; 2(9):950–958. doi:10.1001/jamacardio.2017.2198
    OpenUrlCrossRef
  15. ↵
    1. Cox ZL,
    2. Hung R,
    3. Lenihan DJ,
    4. Testani JM
    . Diuretic strategies for loop diuretic resistance in acute heart failure: the 3T trial. JACC Heart Fail 2020; 8(3):157–168. doi:10.1016/j.jchf.2019.09.012
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Goldsmith SR,
    2. Gilbertson DT,
    3. Mackedanz SA,
    4. Swan SK
    . Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure. J Card Fail 2011; 17(12):982–989. doi:10.1016/j.cardfail.2011.08.012
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hollenberg SM,
    2. Warner Stevenson L,
    3. Ahmad T, et al
    . 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2019; 74(15):1966–2011. doi:10.1016/j.jacc.2019.08.001
    OpenUrlFREE Full Text
  18. ↵
    1. Givertz MM,
    2. Stevenson LW,
    3. Costanzo MR, et al
    . Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 2017; 70(15):1875–1886. doi:10.1016/j.jacc.2017.08.010
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 89 (10)
Cleveland Clinic Journal of Medicine
Vol. 89, Issue 10
1 Oct 2022
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
How do we maximize diuresis in acute decompensated heart failure?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
How do we maximize diuresis in acute decompensated heart failure?
Saeid Mirzai, Christopher N. Kanaan, Felix Berglund, Maria Mountis, Heba Wassif
Cleveland Clinic Journal of Medicine Oct 2022, 89 (10) 561-565; DOI: 10.3949/ccjm.89a.22016

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
How do we maximize diuresis in acute decompensated heart failure?
Saeid Mirzai, Christopher N. Kanaan, Felix Berglund, Maria Mountis, Heba Wassif
Cleveland Clinic Journal of Medicine Oct 2022, 89 (10) 561-565; DOI: 10.3949/ccjm.89a.22016
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • LOOP DIURETICS
    • DIURETIC RESISTANCE
    • OPTIONS FOR AUGMENTING DIURESIS
    • THE BOTTOM LINE
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Decongesting heart failure with diuretics: Easier to prescribe than to fully understand
  • Google Scholar

More in this TOC Section

  • What diagnostic tests should be done after discovering clubbing in a patient without cardiopulmonary symptoms?
  • Does my adult patient need a measles vaccine?
  • Do I need to treat supine hypertension in my hospitalized patient?
Show more 1-Minute Consult

Similar Articles

Subjects

  • Cardiology
  • Hospital Medicine

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire